Brief: Ascletis Pharma Says 3Clpro Inhibitor ASC11 Demonstrated Potential To Be Effective Treatment For COVID-19
19/04/2022 11:03
April 19 (Reuters) - Ascletis Pharma Inc 1672.HK :
* ASCLETIS PHARMA INC - 3CLPRO INHIBITOR ASC11 DEMONSTRATED
POTENTIAL TO BE EFFECTIVE TREATMENT FOR COVID-19
* ASCLETIS PHARMA INC - EXPECTED THAT IND OF ASC11 WILL BE
FILED
IN SECOND HALF OF 2022
* ASCLETIS PHARMA - PHASE I CLINICAL TRIAL IN HEALTHY
SUBJECTS
WILL BE COMPLETED BY END OF 2022
Source text for Eikon: ID:
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026